Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- Conditions
- Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 362
- Registration Number
- NCT04988555
- Locations
- 🇺🇸
Hoag Family Cancer Center, Newport Beach, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Miami, Miami, Florida, United States
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04623996
- Locations
- 🇺🇸
BRCR Global, Plantation, Florida, United States
🇺🇸US Oncology - Austin Texas Oncology Midtown, Austin, Texas, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Phase 1 Study of Oral TP-1454
- Conditions
- Advanced Solid TumorAnal Cancer
- Interventions
- Drug: TP-1454 monotherapy
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04328740
- Locations
- 🇺🇸
Texas Oncology Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
- Conditions
- Oncology
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04299880
- Locations
- 🇯🇵
Kyorin University Hospital, Tokyo, Japan
🇺🇸Maine Center for Cancer Medicine, Scarborough, Maine, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
A Study of Oral TP-3654 in Patients With Myelofibrosis
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04176198
- Locations
- 🇯🇵
Hokkaido University Hospital, Hokkaido, Japan
🇯🇵Mie University Hospital, Tsu, Japan
🇺🇸University of Alabama, Birmingham, Alabama, United States
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03969420
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Orlando Health, Inc, Univ of Florida Health Cancer Center, Orlando, Florida, United States
Study of TP-3654 in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03715504
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: DSP-1349MDrug: placebo
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03627195
- Locations
- 🇺🇸
Dr. David Walling, Long Beach, California, United States
Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
- Conditions
- SarcomaDedifferentiated LiposarcomaSynovial SarcomaAdvanced Solid TumorsEwing Sarcoma
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT03604783
- Locations
- 🇺🇸
US Oncology - Texas Oncology - Tyler, Tyler, Texas, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
🇺🇸US Oncology - Greenville Health System, Greenville, South Carolina, United States
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Combination Product: Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03593915
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸US Oncology - Texas Oncology - Austin Midtown, Austin, Texas, United States